Luiz Henrique Junqueira Dieckmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luiz Henrique Junqueira Dieckmann has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Michel Ferreira Cardia Haddad
Queen Mary University of London, London, United Kingdom
2 shared publications - Paula Dieckmann
Department of Psychiatry, Universidade Federal de São Paulo, São Paulo 04021-001, Brazil
2 shared publications - Altay Alves Lino de Souza
Psychobiology Department, Universidade Federal de Sao Paulo
1 shared publication - André Amaro Mamédio dos Santos
Universidade Estadual de Ponta Grossa
1 shared publication - Anna Carolina Ramos
Department of Psychology, Universidade Federal de Santa Catarina
1 shared publication Barbara Arraes Guedes Macedo
Pontifícia Universidade Católica de São Paulo, Brasil
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 848
Therapeutic Overlap Between Bipolar Disorder and Migraine: A Systematic Review of Pharmacological Trials
Background/Objectives: Migraine is markedly more prevalent among individuals with bipolar disorder (BD) than in the general population. The two disorders share overlapping pathophysiological mechanisms, including neuroinflammation, oxidative stress, and genetic vulnerability. However, the potential bidirectional efficacy of pharmacological agents approved for one condition on the other remains unclear. This study aimed to evaluate cross-disorder pharmacological efficacy between migraine and bipolar disorder. Methods: We systematically searched Medline and the Cochrane Central Register of Controlled Trials (PROSPERO registration: CRD420251130780) for randomized controlled trials (RCTs) assessing (1) concurrent treatment effects in comorbid BD–migraine samples, (2) efficacy of migraine treatments in BD, or (3) efficacy of BD treatments in migraine. Searches included guideline-recommended drugs for either disorder, without language or date restrictions. Results: A total of 32 RCTs met the inclusion criteria. Fifteen studies evaluated migraine drugs in BD, and sixteen evaluated BD drugs in migraine. No RCTs were identified that simultaneously assessed both conditions within the same sample. Valproate was the only agent demonstrating consistent, replicated efficacy in both conditions, supporting true cross-disorder benefit. Haloperidol and chlorpromazine showed limited evidence for acute anti-migraine efficacy, based solely on placebo-controlled studies, whereas all other guideline-recommended BD drugs lacked evidence of benefit for migraine. Conversely, topiramate, while effective for migraine, was inferior to valproate in BD outcomes, and lamotrigine was effective for BD only when compared with placebo. Conclusions: Valproate remains the sole pharmacological agent with robust evidence of bidirectional efficacy in migraine and BD. Most other guideline-recommended medications show disorder-specific effects, highlighting the need for integrative trials addressing pharmacological overlap in comorbid migraine–BD samples.
- 29 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 848
Open AccessTherapeutic Overlap Between Bipolar Disorder and Migraine: A Systematic Review of Pharmacological Trials
Background/Objectives: Migraine is markedly more prevalent among individuals with bipolar disorder (BD) than in the general population. The two disorders share overlapping pathophysiological mechanisms, including neuroinflammation, oxidative stress, and genetic vulnerability. However, the potential bidirectional efficacy of pharmacological agents approved for one condition on the other remains unclear. This study aimed to evaluate cross-disorder pharmacological efficacy between migraine and bipolar disorder. Methods: We systematically searched Medline and the Cochrane Central Register of Controlled Trials (PROSPERO registration: CRD420251130780) for randomized controlled trials (RCTs) assessing (1) concurrent treatment effects in comorbid BD–migraine samples, (2) efficacy of migraine treatments in BD, or (3) efficacy of BD treatments in migraine. Searches included guideline-recommended drugs for either disorder, without language or date restrictions. Results: A total of 32 RCTs met the inclusion criteria. Fifteen studies evaluated migraine drugs in BD, and sixteen evaluated BD drugs in migraine. No RCTs were identified that simultaneously assessed both conditions within the same sample. Valproate was the only agent demonstrating consistent, replicated efficacy in both conditions, supporting true cross-disorder benefit. Haloperidol and chlorpromazine showed limited evidence for acute anti-migraine efficacy, based solely on placebo-controlled studies, whereas all other guideline-recommended BD drugs lacked evidence of benefit for migraine. Conversely, topiramate, while effective for migraine, was inferior to valproate in BD outcomes, and lamotrigine was effective for BD only when compared with placebo. Conclusions: Valproate remains the sole pharmacological agent with robust evidence of bidirectional efficacy in migraine and BD. Most other guideline-recommended medications show disorder-specific effects, highlighting the need for integrative trials addressing pharmacological overlap in comorbid migraine–BD samples.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (11) , e20230690
Correlation between levels of perceived stress and depressive symptoms in the functional disability of patients with fibromyalgia
The aim of this study was to evaluate the factors that are most correlated with the levels of functional disability in patients with fibromyalgia.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (11) , e20230690
Open AccessCorrelation between levels of perceived stress and depressive symptoms in the functional disability of patients with fibromyalgia
The aim of this study was to evaluate the factors that are most correlated with the levels of functional disability in patients with fibromyalgia.
- 1 August 2014
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 24 (8) , 1196-1202
Effects of biperiden on the treatment of cocaine/crack addiction: A randomised, double-blind, placebo-controlled trial
- 1 August 2014
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 24 (8) , 1196-1202
Effects of biperiden on the treatment of cocaine/crack addiction: A randomised, double-blind, placebo-controlled trial
- Open Access
- 1 December 2009
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Educação Médica
- Vol. 33 (4) , 595-604
Factors associated with depressive symptoms in a sample of Brazilian medical students
OBJECTIVES: 1 - Verify the prevalence of depressive symptoms in first to fourth-year medical students using the Beck Depression Inventory (BDI). 2 - Establish correlations between target factors and higher or lower BDI scores. 3 - Investigate the relationship between the prevalence of depressive symptoms and the demand for psychological care offered by the Centro Universitário Lusíada. METHOD: Cross-sectional study of 290 first to fourth-year medical students; implementation of the BDI, socio-demographic survey, and evaluation of satisfaction with progress. RESULTS: The study sample was 59% female and 41% male. Mean BDI was 6.3 (SD 5.8). Overall prevalence of depressive symptoms was 23.1%. The following associations were statistically significant (p<0.05): among students for whom the course failed to meet original expectations, who were dissatisfied with the course, or who came from the interior of the State (20.5%, 12.5%, and 24.4% of the total sample, respectively), for 40%, 36.1% and 36.4%, respectively, the BDI was consistent with some degree of depression. CONCLUSION: The study showed that there is higher prevalence of depressive symptoms in medical students than in the general population
- 1 December 2009
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Educação Médica
- Vol. 33 (4) , 595-604
Open AccessFactors associated with depressive symptoms in a sample of Brazilian medical students
OBJECTIVES: 1 - Verify the prevalence of depressive symptoms in first to fourth-year medical students using the Beck Depression Inventory (BDI). 2 - Establish correlations between target factors and higher or lower BDI scores. 3 - Investigate the relationship between the prevalence of depressive symptoms and the demand for psychological care offered by the Centro Universitário Lusíada. METHOD: Cross-sectional study of 290 first to fourth-year medical students; implementation of the BDI, socio-demographic survey, and evaluation of satisfaction with progress. RESULTS: The study sample was 59% female and 41% male. Mean BDI was 6.3 (SD 5.8). Overall prevalence of depressive symptoms was 23.1%. The following associations were statistically significant (p<0.05): among students for whom the course failed to meet original expectations, who were dissatisfied with the course, or who came from the interior of the State (20.5%, 12.5%, and 24.4% of the total sample, respectively), for 40%, 36.1% and 36.4%, respectively, the BDI was consistent with some degree of depression. CONCLUSION: The study showed that there is higher prevalence of depressive symptoms in medical students than in the general population
- Open Access
- 1 September 2008
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 30 (3) , 296-297
Estratégia de manejo para a disfunção sexual induzida por antipsicóticos: descrição de um relato de caso
Universidade Federal de São Paulo (UNIFESP) Departamento de Psiquiatria Programa de EsquizofreniaUniversidade Federal de São Paulo (UNIFESP) Departamento de PsiquiatriaUNIFESP, Depto. de Psiquiatria Programa de EsquizofreniaUNIFESP, Depto. de PsiquiatriaSciEL
- 1 September 2008
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 30 (3) , 296-297
Open AccessEstratégia de manejo para a disfunção sexual induzida por antipsicóticos: descrição de um relato de caso
Universidade Federal de São Paulo (UNIFESP) Departamento de Psiquiatria Programa de EsquizofreniaUniversidade Federal de São Paulo (UNIFESP) Departamento de PsiquiatriaUNIFESP, Depto. de Psiquiatria Programa de EsquizofreniaUNIFESP, Depto. de PsiquiatriaSciEL